Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx/Aventis Cardizem CD Class Action Appeal Pending; State AGs Sue

Executive Summary

Andrx' appeal of a Detroit federal court summary judgment in a Cardizem CD antitrust class action suit could be decided by the end of the year.
Advertisement

Related Content

AARP Health Litigation Brief Supports Michigan Supplemental Rebates
AARP Health Litigation Brief Supports Michigan Supplemental Rebates
Senate Rx Patent Settlement Bill Revised To Limit Reporting Requirements
Senate Rx Patent Settlement Bill Revised To Limit Reporting Requirements
Barr/AstraZeneca Tamoxifen Settlement Under Investigation By State AGs
Barr/AstraZeneca Tamoxifen Settlement Under Investigation By State AGs
Andrx/Aventis Settle With FTC: Agency Says Cardizem CD Generic Not Delayed
FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
Aventis/Andrx Cardizem CD Deal Violated Antitrust Laws, Judge Says
Aventis/Andrx Cardizem CD Deal Violated Antitrust Laws, Judge Says
Advertisement
UsernamePublicRestriction

Register

PS037846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel